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2Abstract
Expression of the zinc receptor, ZnR/GPR39, is increased in higher grade breast cancer 
tumors and cells. Zinc, its ligand, is accumulated at larger concentrations in the tumor tissue 
and can therefore activate ZnR/GPR39-dependent Ca2+ signaling leading to tumor progression. 
The K+/Cl- co-transporters (KCC), activated by intracellular signaling, enhance breast cancer 
cell migration and invasion. We asked if ZnR/GPR39 enhances breast cancer cell malignancy 
by activating KCC. Activation of ZnR/GPR39 by Zn2+ upregulated K+/Cl- co-transport activity, 
measured using NH4+ as a surrogate to K+ while monitoring intracellular pH. Upregulation 
NH4+ transport was monitored in tamoxifen resistant cells with functional ZnR/GPR39-
dependent Ca2+ signaling but not in MCF-7 cells lacking this response. The NH4+- transport 
was Na+-independent, and we therefore focused on KCC family members. Silencing of KCC3, 
but not KCC4, expression abolished Zn2+-dependent K+/Cl- co-transport, suggesting that KCC3 
is mediating upregulated NH4+- transport. The ZnR/GPR39-dependent KCC3 activation 
accelerated scratch closure rate, which was abolished by inhibiting KCC transport with 
[(DihydroIndenyl) Oxy] Alkanoic acid (DIOA). Importantly, silencing of either ZnR/GPR39 
or KCC3 attenuated Zn2+-dependent scratch closure. Thus, a novel link between KCC3 and 
Zn2+, via ZnR/GPR39, promotes breast cancer cell migration and proliferation. 
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31. Introduction
Estrogen receptor (ER) alpha, which triggers breast cancer cell proliferation, is expressed 
in most breast tumors and thus anti-estrogen drugs, e.g. tamoxifen, became a preferred 
treatment approach [1]. However, relapse occurs in about one third of the patients when anti-
estrogen-resistance develops and tumor subpopulations emerge [2-4]. Mechanisms underlying 
this resistance involve loss of the ER and activation of downstream signaling pathways, such 
as the mitogen activated kinase (MAPK) and phosphatidylinositol 3-kinase (AKT/PI3K), 
independent of estrogen [5, 6]. Notable, expression of a Zn2+-sensing G-protein coupled 
receptor, ZnR/GPR39, is increased in higher stage ER-negative breast cancer tissue and in ER-
negative breast cancer cell lines, compared to ER expressing cells [7]. Activation of 
ZnR/GPR39, by Zn2+, triggered upregulation of MAPK and AKT/PI3K signaling pathways in 
ZnR/GPR39 expressing breast cancer cells. In agreement, unbiased screens identified a 
correlation between upregulation of GPR39 and the aggressiveness of breast cancer cell lines 
and tissues [7, 8]. Changes in Zn2+ levels and in the expression of Zn2+ transporters are also 
monitored in breast cancer tissues [9-12], this dys-homeostasis may trigger release of Zn2+ and 
subsequent activation of ZnR/GPR39. Moreover, injury or cell death of epithelial cells results 
in liberation of Zn2+ from intracellular stores, which is sufficient to activate ZnR/GPR39 [13]. 
In breast cancer cells, ZnR/GPR39 activation compensates for loss of ER signaling and induces 
estrogen-independent activation of MAPK and AKT/PI3K. Thus, ZnR/GPR39 may lead to 
tumor progression via a poorly understood mechanism.
Increased expression and transport activity of members of the K+/Cl− cotransporters 
(KCC1-4) family enhanced tumor progression and invasiveness [14-16]. Under physiological 
conditions, the KCC cotransporters constitute major efflux pathways for K+ and Cl−, and are 
responsible for cell volume regulation, trans-epithelial ion transport and salt absorption. 
However, KCC transporters are also associated with enhanced breast cancer cell proliferation. 
For example, KCC inhibition induced cell cycle arrest, by modulating expression of p21, cyclin 
D1 and cyclin E2 [17]. In addition, upregulation of KCC3 and KCC4 following activation of 
MAPK and AKT/PI3K pathways enhanced breast cancer cell proliferation and migration [16]. 
Overexpression of KCC was also monitored in ovarian and cervical cancer cells and tissues 
[18, 19], and activation of MAPK and AKT/PI3K pathways increased KCC membrane 
expression followed by enhanced proliferation and invasiveness [20-22]. Although 
ZnR/GPR39 is a major regulator of MAPK and AKT/PI3K pathways, it is not known whether 
this pathway upregulates KCC in breast cancer cells. 
In neurons and colonocytes, ZnR/GPR39 is modulating ion transport by upregulating 
KCC2 and KCC1 activity, respectively [23, 24]. Activation of ZnR/GPR39 by synaptically 
4released Zn2+ enhances neuronal KCC2 activity and the Cl− inward gradient. Thus, ZnR/GPR39 
hyperpolarizes the reversal potential of GABAA–mediated Cl- currents and reduces 
susceptibility to seizures [25]. In colonocytes, KCC1 is expressed on the basolateral membrane, 
and ZnR/GPR39-dependent upregulation of KCC1 enhances Cl− absorption and decreases 
water loss [24]. Activation of ZnR/GPR39 and subsequently KCC1 reduces cholera toxin 
induced diarrhea, providing a mechanism for the established role of Zn2+ in reducing diarrhea 
[24]. We therefore reasoned that ZnR/GPR39 may activate KCC and thereby promote breast 
cancer progression. Here, we show that ZnR/GPR39 activation in tamoxifen-resistant breast 
cancer cells upregulates KCC3 activity and enhances cell proliferation and migration. 
2. Materials and Methods
Cell culture: MCF-7 cells, a human breast cancer cell line, were cultured in phenol-red 
RPMI medium supplemented with 5% fetal calf serum, and penicillin-streptomycin (10 IU/ml 
10 g/ml). TAMR cells [26], MCF-7 cells resistant to 4-hydroxytamoxifen (4-OH-TAM), were 
cultured in phenol-red-free RPMI medium supplemented with 5% charcoal-stripped steroid-
depleted fetal calf serum plus penicillin-streptomycin, 4 mM L-glutamine and 4-OH-TAM (10-
7 M in ethanol) (Gibco). For imaging measurements, 1,000,000 cells were seeded onto 10 mm 
glass coverslips and imaged after 48 h as described below. MCF-7 cells that were seeded for 
imaging measurements were grown in phenol-red-free RPMI medium.
Silencing: For gene-silencing experiments, cells were transfected with siGPR39/KCC3/ 
KCC4 or a scrambled (si-control) siRNA construct (40nM, Sigma-Aldrich) in 60 mm plates, 
using the transfection reagent Dharmafect as described by the manufacturer (Thermo-
scientific). Cells were imaged or used for qPCR analysis 48 h after transfection. The target 
sequence of the GPR39 for siRNA was: sense 5' CCATGGAGTTCTACAGCATtt, anti-sense: 
5' ATGCTGTAGAACTCCATGGtt. The target sequence of the si-control for siRNA was: 
sense 5' GCCCAGATCCCTGTACGTtt, anti-sense 5' ACGTACAGGGATCTGGGCtt. The 
target sequence of the KCC3 for siRNA was: sense 5' CGGACATAAGAAAGCTCGAtt, anti-
sense 5' TCGAGCTTTCTTATCTCCGtt. The target sequence of the KCC4 for siRNA was: 
sense 5' GGTGGAACAAGAGAGCTTCtt, anti-sense 5' GAAGCTCTCTTG TTCCACCtt. 
PCR was used to estimate the presence of KCC family members in MCF-7 and TAMR cells. 
Cells were seeded on 60 mm plates, after 48 hours cells were trypsinized with 0.05% trypsin 
(Biological Industries). Cell lysates were homogenized using QIAshredder, as described by the 
manufacturer (QIAGEN). Total RNA was purified using RNeasy Mini Kit as described by the 
manufacturer (QIAGEN). Purified RNA (1μg) was converted to cDNA using synthesis Kit 
(Life Technologies). The cDNA was used for PCR analysis with the Red load TaqMaster 
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TGGGACCATTTTCCTGACC reverse: CATGCTTCTCCACGATGTCAC; KCC3 
(recognizes all variants): forward: GCCCGAAACACAAAATCACT reverse: GGATACCTG 
GGGGAAGATGT; KCC4: forward: GACTCGTTTCCGCAAAACC reverse: AGAGTG 
CCGTGATGCTGTTGG. The same cDNA was diluted at 1:5 and subjected to real time PCR 
procedure (Taqmen, Applied Biosystems), which was done with ABsolute Blue QPCR kit 
(Thermo Scientific). Required primers and probes were predesigned and supplied by Solaris: 
KCC1 (recognizes 1,2,4,5,6 variants): forward: CTGGCACTGTTTGAGGAAGA reverse: 
GCTTTC CCAGAAGAGACGAT probe: TCCGCCCAAAGGTATCG; KCC3 (recognizes all 
variants): forward: CCTAATGGCTGGCGTCAA reverse: ATGGGCAGCAGTTGT CACTC 
probe: CTT TTATTGGCACAGTTCG; KCC4 forward: TACCTGGACAAGCA CATGGA 
reverse: GCT CATTAGGGACCGTAT probe: GCGGGCCGAGGAGAACATAC.
Ion transport experiments: Cells grown on coverslips were loaded at room temperature 
with 1μM 2′,7′-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF-AM, 10 min, Tef Labs) 
or 5μM Fura-2 AM (20 min, Tef Labs) in Ringer’s solution composed of (in mM): 120 NaCl; 
5.4 KCl; 1.8 CaCl2; 0.8 MgCl2; 10 HEPES; 10 glucose; pH 7.4, containing 0.1% bovine serum 
albumin. Cells were then washed twice in Ringer’s solution containing 0.1% bovine serum 
albumin and incubated for an additional 20 min at room temperature. Treatment with 
extracellular Zn2+ and inhibitors was done immediately prior to imaging, as indicated for each 
experiment. Coverslips were then mounted in a perfusion chamber of a Zeiss Axiovert 200 
microscope and images were acquired every 3s (Indec Imaging Workbench 5) using a 10× 
objective with 4 × 4 binning of the image (Sensi-Cam, PCO), as done previously [23]. BCECF 
was excited at 440 nm and 470 nm while Fura-2 was excited at 340 nm and 380 nm, with 
polychrome monochromator (TILL Photonics), both were imaged with a 510-nm long-pass 
filter. The fluorescent signal is presented as the ratio between the two wavelengths 
(R=F440/F470 or R=F340/F380). All results shown are traces of the averaged responses of ~60 
cells in each experimental paradigm, for each condition at least 3 independent experiments. As 
marked in the graphs, n represents the number of slides used for each treatment.
NH4Cl paradigm: Cells were perfused with K+-free Ringer's solution to obtain baseline 
fluorescence and then NH4Cl was added (30mM to TAMR cells and 15mM to MCF-7 cells) 
while monitoring BCECF fluorescence. In a set of experiments, N-methyl-d-glucamine 
(NMDG, 120mM) replaced NaCl in the Ringer's solution yielding a Na+-free solution. 
Application of NH4Cl, due to the resting equilibrium with NH4+, induces diffusion of NH3 into 
the cells and alkalinization of the cells. The inward gradient of NH4+, acting as a surrogate to 
K+, activates ion transporters and intracellular NH4+ induces cellular acidification. The rate of 
NH4+ influx (that is the rate of acidification), determined using a linear fit of the decrease in 
6fluorescent signal during a 60s period following the peak, represents transporter activity, as 
previously described [23, 27]. 
In-Vitro Scratch Assay: Cells were seeded at 4×104 cells/ well in 96-well plates, grown to 
confluency and then deprived of serum for 24h. A scratch was performed using 200µl plastic 
pipette tip (~2 mm in width), as previously described [13], in 37°C Ringer’s solution with 
Ethylenediaminetetraacetic acid (EDTA) (100µM), a concentration that does not affect Ca2+ 
levels but chelate any residual Zn2+ that may activate ZnR/GPR39. Cells were then treated with 
Zn2+ (200µM) or EDTA (100µM) for 10 min and subsequently washed extensively. The 
Ringer’s solution was then replaced back to phenol-red-free RPMI medium supplemented with 
1% fetal calf serum plus penicillin-streptomycin, 4 mM L-glutamine. The Gq inhibitor 
YM254890 (1µM, 30 min) or KCC inhibitor DIOA (20µM, 30 min) were applied 30 min prior 
to scratching (DMSO at the same concertation was used as control). siRNA transfection was 
done 48h prior scratching. The percentage of scratch closure was determined by acquiring 
bright field images immediately after performing the scratch, and after 24h. Area measurements 
of the cell-free region were performed using ImageJ software, and the ratio of denuded areas at 
these times are presented.
Statistical analysis: Each bar graph represents an average±S.E.M of at least three 
independent experiments. Statistical analysis was performed using paired Student’s t-test, 
comparing each treatment to Zn2+ treatment unless otherwise mentioned. * p < 0.05; ** p < 
0.01; *** p<0.001.
3. Results
 Since both ZnR/GPR39 and KCC enhance breast cancer cell proliferation, we asked if 
ZnR/GPR39 regulates KCC ion transport activity. Activation of ZnR/GPR39 primarily 
mediates Zn2+-dependent Ca2+ release via the Gq-IP3 pathway [28-30]. Using the Ca2+-sensitive 
fluorescent dye, Fura-2, we monitored Zn2+-dependent Ca2+ release in tamoxifen resistant 
TAMR cells (Fig. 1A).  The response was triggered by a brief exposure to 200µM Zn2+, which 
activates ZnR/GPR39 in breast cancers cells but does not induce intracellular Zn2+ rise [7]. 
Importantly, such transient rises likely imitate Zn2+ release from cellular vesicles found in the 
mammary gland cells or Zn2+ liberation following cell death [13, 31, 32]. But Zn2+-dependent 
Ca2+ responses were absent in MCF-7 breast cancer cells (Fig. 1B), from which the TAMR cells 
were derived [26, 33]. To compare whether this signaling induced Zn2+-dependent transport 
activity in TAMR or MCF-7 cells, we used the well-established NH4Cl transport paradigm in 
which NH4+ serves as a surrogate for K+ and its transport affects intracellular pH that is 
monitored with BCECF [23, 24]. Application of Zn2+, at concentrations that activated 
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treated cells (Fig. 1C, F). In contrast, application of Zn2+ to MCF-7 cells failed to enhance rates 
of ion transport (Fig. 1D, F). To determine the specific role of ZnR/GPR39, we silenced this 
receptor using siRNA constructs (siGPR39, Fig. 1E) in TAMR cells. Control cells transfected 
with a scrambled construct (si-control) showed Zn2+-dependent Ca2+ signaling, but transfection 
of TAMR cells with siGPR39 resulted in loss of this signaling (Fig. 1E inserts). Purinergic 
response to ATP, triggered a similar intracellular Ca2+ release in si-control and siGPR39 cells 
indicating that the Gq-IP3 pathway was intact. We then monitored NH4+ transport in cells 
treated with or without Zn2+. The Zn2+-dependent enhancement of NH4+ transport was 
maintained in si-control cells (Fig. 1E middle panel), but in siGPR39 transfected cell Zn2+ failed 
to upregulate ion transport rates (Fig. 1E right panel). Thus, ZnR/GPR39 is essential for Zn2+-
dependent activation of NH4+ transport in breast cancer cells (Fig. 1F). 
Since NH4+ transport may be mediated by Na+-dependent NKCC transporters or Na+-
independent KCCs [34], we asked if the presence of Na+ is essential for ZnR/GPR39 
upregulation of ion transport. When NMDG replaced Na+ in the perfusing solution, application 
of Zn2+ increased ion transport rates to a similar level as monitored in the presence of Na+ (Fig. 
2A-B). This result suggests that the Zn2+-dependent increase in ion transport is mediated by a 
Na+-independent KCC. Similarly, an inhibitor of NKCC subfamily, bumetanide (1µM, a 
concentration that does not affect KCC-dependent transport) did not attenuate the Zn2+-
dependent upregulation of ion transport in TAMR cells (Fig. 2C). In contrast, the KCC inhibitor 
[(DihydroIndenyl) Oxy] Alkanoic acid (DIOA, 20μM or 100μM) abolished Zn2+-dependent 
upregulation of NH4+ transport in TAMR cells (Fig. 2D-E). This set of results suggests that 
KCC activity is upregulated by ZnR/GPR39 (Fig. 2F). 
We next asked which of the KCC family members is regulated by Zn2+ in TAMR cells. 
The Zn2+-dependent Ca2+ signaling found in TAMR cells, correlated with increased 
ZnR/GPR39 mRNA expression in the TAMR cells compared to MCF-7 cells [7]. We then 
asked KCC mRNA expression is also different between these cells. We found higher mRNA 
expression of KCC3 and KCC4, but not KCC1, in TAMR compared to MCF-7 cells (Fig. 3A). 
We therefore focused on KCC3 and KCC4 asking if they are regulated by ZnR/GPR39. First, 
we monitored NH4+ transport in BCECF loaded TAMR cells that were transfected with a 
scrambled siRNA construct (si-control). Upregulation of NH4+ transport by Zn2+ was 
maintained in si-control cells compared to transport rates in cells not treated with Zn2+ (Fig. 
3B). In contrast, silencing of KCC3 expression attenuated Zn2+-dependent increase of NH4+ 
transport rate (siKCC3,Fig. 3C, E). Upregulation of transport by Zn2+ was maintained in 
siKCC4 transfected cells (Fig. 3D, E). Altogether this set of experiments indicates that silencing 
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cells (Fig. 3E), suggesting that Zn2+ upregulates KCC3-dependent transport.  
Finally, we asked whether Zn2+ via ZnR/GPR39-dependent upregulation of KCC3 
enhances breast cancer cell proliferation and migration by using a scratch assay. First, we 
compared scratch closure between TAMR cells, expressing a functional ZnR/GPR39, and 
MCF-7 cells, deficient in ZnR/GPR39. Application of Zn2+, at a concertation that selectively 
activates ZnR/GPR39, enhanced rates of scratch closure in TAMR cells (Fig. 4A, F) but not in 
MCF-7 cells (Fig. 4B, F). To determine the role of ZnR/GPR39 downstream signaling, we 
treated TAMR cells with a Gq inhibitor (YM254890, 1µM) that inhibits ZnR/GPR39-
dependent Ca2+ signaling [13]. Note that Zn2+ failed to enhance scratch closure when cell were 
treated with this Gq inhibitor (Fig. 4C, F). To specifically determine the role of ZnR/GPR39, 
cells were transfected with siGPR39 or si-control. We found that scratch closure rates were 
enhanced by Zn2+-treatment in si-control cells (Fig. 4D, F), but not in siGPR39 transfected cells 
(Fig. 4E, F). Altogether these results suggest that Zn2+-dependent cell growth is mediated by 
ZnR/GPR39. Next, we tested whether accelerated scratch closure rates were mediated by KCC 
activity. In the presence of DIOA, Zn2+ treatment failed to accelerate rates of scratch closure, 
(Fig. 5A, D). Since KCC3 activity was upregulated by Zn2+ (Fig. 3), we then transfected cells 
with siKCC3 and determined its direct role in cell migration and proliferation. Zn2+ did not 
enhance rates of scratch closure in cells transfected with siKCC3 but was effective in cells 
transfected with si-control (Fig. 5B-C, D). Thus, we suggest that Zn2+ via ZnR/GPR39 activates 
KCC3 and thereby enhances rates of scratch closure in ZnR/GPR39-expressing TAMR cells. 
4. Discussion 
The ZnR/GPR39 pathway was previously shown to induce Ca2+ release and downstream 
activation of ion transport, which was essential for regulating ion gradients, absorption and cell 
growth [13, 23, 24, 35, 36]. We now provide evidence for a role of ZnR/GPR39 in upregulating 
KCC3-dependent ion transport and leading to enhanced breast cancer cell proliferation and 
migration. The Zn2+-dependent Ca2+ release triggered by ZnR/GPR39 was essential for 
upregulation of ion transport activity in TAMR cells, as NH4+ transport was diminished 
following silencing of ZnR/GPR39. In agreement, MCF-7 cells lacking ZnR/GPR39 do not 
show Zn2+-dependent upregulation of transport activity. Finally, activation of both ZnR/GPR39 
and KCC3 was essential to enhance scratch closure in TAMR breast cancer cells. 
 Activation of ZnR/GPR39 signaling cascade by Zn2+ enhanced scratch closure in 
keratinocytes, skin cells [13, 37], and was associated with a well-known role of zinc in 
enhancing wound healing. Similarly, enhanced proliferation was induced by ZnR/GPR39 in 
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changes in extracellular Zn2+, and release of this ion from injured cells was sufficient to activate 
ZnR/GPR39 signaling [13]. Malignant tumors in-vivo are characterized by regions of cell death 
due to lack of oxygen, glucose and/or other nutrients [42, 43]. Such massive cell death can 
trigger extracellular Zn2+ transients and activate ZnR/GPR39 in neighboring breast cancer cells. 
In addition, breast epithelial cells accumulate large amounts of Zn2+ in lysosomes [44-46], and 
express multiple Zn2+ transporters that maintain the distribution of this ion in cellular 
compartments [47]. As Zn2+ transporters expression is modulated in breast tumor tissue [5, 9, 
48], aberrant Zn2+ transport can induce release of Zn2+ and also trigger activation of 
ZnR/GPR39. Finally, release of lysosomal ATP from breast cancer cells following TRPML1 
activation [49] may also induce release of Zn2+ that is selectively stored in this organelle. Thus, 
numerous sources for transient Zn2+ release in the tumor microenvironment can activate 
ZnR/GPR39 and subsequent KCC3 upregulation that will promote tumor progression. 
Several studies associated ZnR/GPR39 with cancer and tumor growth, but the role of Zn2+-
dependent signaling was not specifically addressed. For example, levels of ZnR/GPR39 were 
higher in breast cancer tumors compared to benign biopsies [7, 8, 50]. Similar increase in 
ZnR/GPR39 was monitored during epidermal wound healing, at a stage of maximal growth 
when the epidermis was thickest [37]. In esophageal squamous cell carcinoma (ESCC), 
ZnR/GPR39 was found to contribute to cell growth, foci formation and metastasis via activation 
of cyclin D1 [51]. In addition, in HT29 cells, a colorectal adenocarcinoma cell line, silencing 
ZnR/GPR39 attenuated cell growth while activation of ZnR/GPR39 reduced butyrate-induced 
apoptosis [40]. In breast cancer cells, ZnR/GPR39-dependent activation of MAPK and 
AKT/PI3K enhanced proliferation and migration [7]. Here, we show that Zn2+-dependent 
enhancement of proliferation and migration of TAMR breast cancer cells requires activation of 
both ZnR/GPR39 and the K+/Cl- cotransporter, KCC3. 
Solute and ion secretion by epithelial cells controls cell volume, which also regulates the 
activity of KCC1, KCC3 and KCC4 [34, 52]. Regulation of cell volume involves re-
organization of the actin cytoskeleton. Indeed, the guanine nucleotide exchange factor, Vav2, 
which is responsible for cell spreading, interacts with KCC3 via a proline rich domain and this 
interaction localizes KCC3 to actin rich membrane protrusions [53]. Similar changes in the 
actin cytoskeleton are required for lamellipodia formation and cell migration, processes that 
play an important role in cancer metastasis. Our data indicate that ZnR/GPR39 upregulation of 
KCC3 activity is required to enhance cell migration. This is based on reduced scratch closure 
following either: silencing of ZnR/GPR39, inhibition of its downstream signaling or silencing 
of KCC3 (Fig. 4-5). It would be interesting to determine in future studies if ZnR/GPR39 
upregulation of KCC3 activity affects actin cytoskeleton and thereby cell migration.
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Activation of KCC3 and KCC4 by IGF-1 and downstream MAPK pathway enhanced 
MCF-7 breast cancer cell proliferation, epithelial mesenchymal transition and migration of 
these cancer cells [16, 20, 54]. Activation of MAPK was essential to mediate ZnR/GPR39-
dependent activation of KCC2 in neurons [23]. Upregulation ZnR/GPR39 was observed in 
estrogen receptor deficient breast cancer cells, and involved activation of MAPK and 
AKT/PI3K pathways in TAMR cells [7]. Our results indicate that even though both KCC3 and 
KCC4 mRNA were increased in TAMR cells compared to MCF-7, the Zn2+-dependent 
ZnR/GPR39 signaling pathway upregulated KCC3 activity, but not KCC4. Moreover, silencing 
of KCC3 reduced ZnR/GPR39-dependent scratch closure, suggesting that in this model KCC3 
is the major mediator of Zn2+ and ZnR/GPR39 dependent cell proliferation. Activity of KCC3 
was also essential for the ZnR/GPR39-dependent growth effect, as it was abolished by 
application of DIOA, an inhibitor of the transport itself. Similarly, activation of KCC3-
dependent transport was required for proliferation of cervical cancer cells and KCC3 specific 
localization in lamellipodia was associated with their migration [53, 55]. Our data show that 
ZnR/GPR39 activates KCC3-dependent ion transport to enhance breast cancer proliferation and 
migration. 
In this study, we provided evidence that activation of Zn2+-dependent ZnR/GPR39 
signaling cascade results in breast cancer growth mediated by KCC3. Both ion transport and 
GPCRs are targeted in cancer treatment [56-58], developing treatment that will target 
ZnR/GPR39-dependent KCC3 activation in breast cancer tissue could effectively attenuate 
tumor progression.
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Figure Legends:
Figure 1: Zn2+-dependent up regulation of ion transport is mediated by ZnR/GPR39. (A) 
TAMR or (B) MCF-7 cells were loaded with Fura-2 and fluorescence was monitored in the 
respective cells following application of Zn2+ (200µM) to trigger ZnR/GPR39 response, or ATP 
to activate purinergic signaling, as control. (C) TAMR or (D) MCF-7 cells loaded with BCECF 
(0.5µM) were superfused with K+ free Ringer's solution. At the indicated time, NH4Cl was 
added (30 mM for TAMR cells and 15 mM for MCF-7 cells) and changes in BCECF 
fluorescence were monitored (see Methods). To activate ZnR/GPR39, prior to imaging, cells 
were pre-treated with Zn2+ (200µM, 2 min, grey trace) or without it, as control (black trace). 
(N=14 or 21, in control or Zn2+ treated respectively) (E) TAMR cells were transfected with 
scrambled siRNA sequence (si-control) or with siRNA sequence aimed to silence ZnR/GPR39 
(siGPR39). Left panel shows mRNA expression level of ZnR/GPR39 following transfection. 
The NH4+ paradigm was applied to si-control (middle panels) or siGPR39 (right panels) 
transfected cells that were pre-treated with or without Zn2+, as in B (N=10 slides for si-control 
or siGPR39). Insets in middle and right panels show Fura-2 fluorescence monitored in si-
control or siGPR39, respectively. (F) Averaged rates of NH4+ -dependent acidification as 
monitored in C-E (N= number of slides in 4 independent experiments for each paradigm, *, 
p<0.05, N.S. is non-significant; between Zn2+ treated and control cells for each independent 
paradigm). 
Figure 2: ZnR/GPR39-dependent transport in TAMR cells is mediated by a KCC. (A) 
TAMR cells were pre-treated with Zn2+ (200µM, grey traces) or without it (black traces) to 
trigger ZnR/GPR39-dependent ion transport as measured using the NH4+ paradigm (see Fig. 1). 
(B) TAMR cells were superfused with NMDG containing Ringer's solution (replacing Na+) and 
pre-treated with or without Zn2+ as in A. (C) The NKCC blocker, bumetanide (1µM) was 
applied prior to the NH4+ paradigm (application of 30mM NH4Cl to BCECF loaded cells, see 
Methods). Cells were pre-treated with or without Zn2+ and ion transport measured as in A. (D) 
Cells were incubated with the KCC inhibitor, DIOA (100µM), and the NH4+ paradigm was 
applied with or without Zn2+ treatment. (E) Cells were incubated with DIOA (20µM). (F) 
Averaged rates of NH4+ transport in TAMR cells as monitored in A-E (N=12 or 15 slides, in 
control or Zn2+ treated respectively, in 3 independent experiments for each paradigm, *, p<0.05, 
N.S. is non-significant; between Zn2+ treated and control cells for each independent paradigm). 
Figure 3: ZnR/GPR39-dependent transport in TAMR cells is mediated by KCC3. (A) 
mRNA expression levels of KCC family members and ZnR/GPR39 were measured using 
qPCR, in MCF-7 and TAMR cells. mRNA levels were normalized to the expression in MCF-
7 cells (N=3). (B) The NH4+ paradigm was applied to TAMR cells (application of 30mM NH4Cl 
to BCECF loaded cells, see Methods) that were transfected with scrambled (si-control) siRNA 
constructs and cells were treated with or without Zn2+ as in Fig. 1. (C) TAMR cells were 
transfected with siKCC3 or (D) siKCC4 and the NH4+ paradigm was performed (30mM NH4Cl 
to BCECF loaded cells) in cells treated with or without Zn2+ as in Fig. 1. Insets in C-D indicate 
the mRNA expression levels of KCC after transfection with the indicated siRNA construct. (E) 
Averaged rates of NH4+ transport in TAMR cells as monitored in B-D (N=16 or 18 slides, in 
control or Zn2+ treated respectively, in 3 independent experiments for each paradigm, *, p<0.05, 
N.S. is non-significant; between Zn2+ treated and control cells for each independent paradigm). 
Figure 4: Zn2+, via ZnR/GPR39, enhances scratch closure rates in TAMR cells. TAMR 
cells (A) and MCF-7 cells (B) were grown to confluence, and a scratch was performed in the 
presence of EDTA (100µM) to chelate residual Zn2+. Cells were treated with or without Zn2+ 
(200µM, 10min, N=41-69 wells for each treatment). (C) TAMR cells were pre-treated with the 
16
Gq inhibitor, YM254890 (1µM, N=21 wells for each treatment) and the scratch assay was 
performed as in A. (D) TAMR cells were transfected with si-control or (E) siGPR39, and the 
scratch assay was performed as in A (N=14 wells for each treatment). (A-E) For each condition 
representative images are shown, of cell cultures immediately after scratch (top panels, 0h) and 
at 24h (bottom panels), and with Zn2+ treatment (right panels) or without it (left panels). (F) 
The average of void area closure (difference between area of void at 0h and at 24h) normalized 
to the initial void area, representing the percentage of scratch closure over 24h for cells treated 
with Zn2+ (grey bars) or without it (black bars, control). (N=number of wells in 3 independent 
experiments for each condition; *, p<0.05, N.S. is non-significant; between Zn2+ treated and 
control cells for each independent paradigm). 
Figure 5: ZnR/GPR39 enhances scratch closure rates via KCC3 in TAMR breast cancer 
cells. TAMR cells were used for the scratch assay as in Figure 4. (A) Cells were treated with 
DIOA (20µM) and then with or without Zn2+ (200µM, N=37-41 wells for each treatment) prior 
to performing the scratch. (B) TAMR cells were transfected with si-control or (C) siKCC3 and 
the scratch assay was applied (N=20 wells for each treatment). For each condition 
representative images are shown, of cell cultures immediately after scratch (top panels, 0h) and 
at 24h (bottom panels), and with Zn2+ treatment (right panels) or without it (left panels). (D) 
The average of void area closure (difference between area of void at 0h and at 24h) normalized 
to the initial void area, representing the percentage of scratch closure over 24h for cells treated 
with Zn2+ (grey bars) or without it (black bars, control). (N=number of wells in 3 independent 
experiments for each condition; *, p<0.05, N.S. is non-significant; between Zn2+ treated and 
control cells for each independent paradigm). 
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